MYCN and neuroblastoma: Interestingly, DHX9 was among RBPs upregulated in MYCN-amplified high-risk neuroblastoma samples of our cohort (p = 5e−3, Fig. 4c) and of an independent published cohort34 that we re-analyzed (92 with and 401 lacking MYCN amplifications, p < 1e−16, Fig. 4d).